GR 103691
SIGMA/G0544 - ≥98% (HPLC), solid
Synonym: 4′-Acetyl-N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-[1,1′-biphenyl]-4-carboxamide
CAS Number: 162408-66-4
Empirical Formula (Hill Notation): C30H35N3O3
Molecular Weight: 485.62
MDL Number: MFCD00936840
Linear Formula: C30H35N3O3
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| form | solid |
| InChI | 1S/C30H35N3O3/c1-23(34)24 |
| InChI key | JARNORYOPMINDY-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100  |
| SMILES string | COc1ccccc1N2CCN(CCCCNC(=O |
| solubility | DMSO: soluble >5 mg/mL at 60 °C |
| storage temp. | 2-8°C |
| Application: | GR 103691 has been used as a D3 receptor antagonist to test its: • inducing effect on prepulse inhibition (PPI) • suppressive effect of motor behavior in rats • inhibitory effect on chemotaxis in newly excysted juvenile C. sinensis (CsNEJs) |
| Biochem/physiol Actions: | D3 dopamine receptor antagonist. |
| Biochem/physiol Actions: | GR 103691 increases the monosynaptic “stretch” reflex (MSR) amplitude in mice by its potent D3 receptor antagonist functionality. It inhibits the PD 128,907 mediated γ-aminobutyric acid (GABA) release. |
| Features and Benefits: | This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Legal Information: | Sold for research purposes under agreement from GlaxoSmithKline |
| Packaging: | 10 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |